Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer

European Journal of Cancer

Volumn 49, Issue 6, 2013, Pages 1169-1175

  Infante, Jeffrey R ^a   Bendell, Johanna C ^a   Goff, Laura Williams ^b   Jones, Suzanne F ^a   Chan, Emily ^b   Sudo, Tomohiro ^c   Burris, Howard A ^a   Berlin, Jordan D ^b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

A33; Dose escalation; KRN330; Phase I; Solid tumours

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN; KRN 330; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; CANCER CONTROL; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; FEVER; FIRST IN HUMAN STUDY; FLATULENCE; FLUSHING; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; IMMUNOGENICITY; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA; PERIPHERAL EDEMA; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RASH; SIDE EFFECT; TREATMENT DURATION; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; COLORECTAL NEOPLASMS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 84875735557     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.11.033     Document Type: Article

References (16)

1. M.J. Hayat, N. Howlader, M.E. Reichman, and B.K. Edwards Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program Oncologist 12 1 2007 20 37
2. M. El Zouhairi, A. Charabaty, and M.J. Pishvaian Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents Gastrointest Cancer Res 4 1 2011 15 21
3. C.H. Kohne, and H.J. Lenz Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer Oncologist 14 5 2009 478 488
4. J. Rageul, S. Mottier, and A. Jarry KLF4-dependent, PPAR gamma-induced expression of GPA33 in colon cancer cell lines Int J Cancer 125 12 2009 2802 2809
5. P.M. Pereira-Fantini, L.M. Judd, and A. Kalantzis A33 antigen-deficient mice have defective colonic mucosal repair Inflamm Bowel Dis 16 4 2010 604 612
6. J.K. Heath, S.J. White, and C.N. Johnstone The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily Proc Natl Acad Sci U S A 94 2 1997 469 474
7. P. Garinchesa, J. Sakamoto, S. Welt, F. Real, W. Rettig, and L. Old Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy Int J Oncol 9 3 1996 465 471
8. S. Welt, C.R. Divgi, and N. Kemeny Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer J Clin Oncol 12 8 1994 1561 1571
9. S. Welt, A.M. Scott, and C.R. Divgi Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer J Clin Oncol 14 6 1996 1787 1797
10. I. Ishida, K. Tomizuka, H. Yoshida, T. Tahara, N. Takahashi, and A. Ohquma Production of human monoclonal and polyclonal antibodies in TransChromo animals Cloning Stem Cells 4 1 2002 91 102
11. N. Sawada, E. Taguchi, and M. Takahashi In vitro and in vivo activities of KRN330, a fully human monoclonal antibody against colon cancer J Clin Oncol Suppl. 4 2011 Abstract 432
12. Berlin JD, Infante JR, Taguchi E, et al. In vivo antibody binding to tumor in colorectal cancer patients and xenograft rodent models treated with anti-A33 antibody KRN330. Presented at the 2010 American Association for Cancer Research Meeting 2010; Abstract 2431.
13. Declaration of Helsinki. World Medical Association. < http://www.wma.net/e/ethicsunit/helsinki.htm />; 2012 [accessed 02.10.12].
14. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
15. J.C. Bendell, J. Marshall, H.S. Berlin, and H. Hochster KRN330, a fully human antibody against A33, in combination with irinotecan for patients with metastatic colorectal cancer (mCRC) J Clin Oncol Suppl. 4 2011 Abstract 534
16. S. Welt, G. Ritter, and C. Williams Jr. Phase I study of anticolon cancer humanized antibody A33 Clin Cancer Res 9 4 2003 1338 1346